Form 4: Arcus Biosciences CFO Receives Stock Options and Restricted Stock Units

Arcus Biosciences' Chief Financial Officer, Robert C. Goeltz II, was granted 150,000 stock options and 37,000 restricted stock units on January 23, 2025.

Summary

• Robert C. Goeltz II, the Chief Financial Officer of Arcus Biosciences, received 150,000 stock options and 37,000 restricted stock units on January 23, 2025.
• The stock options have an exercise price of $13.33 and become exercisable in 48 equal monthly installments starting after January 1, 2025.
• The restricted stock units vest in four equal annual installments beginning December 15, 2025.
• Both the stock options and restricted stock units are subject to Mr. Goeltz's continued service with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.

Positives

• The grants of stock options and restricted stock units align the CFO's interests with those of the shareholders.
• The vesting schedules for both grants encourage long-term commitment from the CFO.

Risks

• The value of the stock options and restricted stock units is dependent on the future performance of Arcus Biosciences' stock price.
• If the CFO leaves the company before the vesting periods are complete, the unvested options and units will be forfeited.

Future Outlook

The vesting of the stock options and restricted stock units is contingent on the CFO's continued service to the company.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option and restricted stock unit grants are standard compensation practices for executives in the biotech industry.
• Companies like Gilead Sciences and Amgen also use similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedules are typical for executive grants, encouraging long-term commitment.

Stakeholder Impact

• Shareholders may view the grants positively as they align the CFO's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, Arcus Biosciences, RCUS, CFO, Robert C. Goeltz II